Am. J. Respir. Crit. Care Med., Volume 156, Number 5, November 1997, 1371-1376

Treatment of Progressive Pulmonary Sarcoidosis with Cyclosporin A
A Randomized Controlled Trial

CHRISTOPH P. WYSER, EMMERENTIA M. van SCHALKWYK, BERTHOLD ALHEIT, PHILIP G. BARDIN, and JAMES R. JOUBERT

Department of Internal Medicine and Stellenbosch University Pulmonary Unit for Research, Cape Town, South Africa

Conventional treatment of sarcoidosis is often only partially effective. We examined the effect of cyclosporin A (CsA) combined with prednisone for the treatment of sarcoidosis. Thirty-seven patients with biopsy-proven sarcoidosis were treated with either prednisone 20 mg/d in a prospectively tapered regimen (P) or with combination therapy consisting of prednisone 20 mg/d in a prospectively tapered regimen and cyclosporin A, 5 to 7 mg/kg/d (P-CsA) for up to 18 mo in an open-label randomized controlled trial. Evaluation was done at baseline and at 3, 9, and 18 mo of the degree of dyspnea, pulmonary function, chest radiographs, bronchoalveolar lavage (BAL), and adverse events. Criteria for a good therapeutic response, improvement, treatment failure, and relapse were defined. Thirty-seven patients were treated for at least 9 mo and 18 for at least 18 mo. Six patients in remission were included in an intention-to-treat-analysis at 18 mo. The groups did not differ significantly with respect to therapeutic response from baseline. A significant (p < 0.05) improvement was observed in dyspnea until 9 mo (P) and 18 mo (P-CsA), and in lung function until 9 mo (P) and 3 mo (P-CsA). BAL results showed a significant decrease in lymphocyte counts at 9 mo for the P group only (p < 0.05). More side effects were observed in the P-CsA group than in the P group, including elevation of the mean serum creatinine concentration at 3 and 9 mo (p < 0.05), and a doubling of the number of infections in this group. Relapse after an initially good therapeutic response occurred in two of nine patients in the P group and five of seven patients in the P-CsA group (p < 0.07). Although CsA may have theoretical benefits in the treatment of sarcoidosis, our results do not support its use in this disease.

This article has been cited by other articles:

				J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]

				A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]

				S. E. Weinberger A 47-year-old woman with sarcoidosis. JAMA, November 1, 2006; 296(17): 2133 - 2140. [Abstract] [Full Text] [PDF]

				J. C. Grutters and J. M. M. van den Bosch Corticosteroid treatment in sarcoidosis. Eur. Respir. J., September 1, 2006; 28(3): 627 - 636. [Abstract] [Full Text] [PDF]

				N. Milman, C. B. Andersen, C. M. Burton, and M. Iversen Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells Eur. Respir. J., September 1, 2005; 26(3): 549 - 552. [Abstract] [Full Text] [PDF]

				V. Majithia, S. Sanders, V. Harisdangkul, and J. G. Wilson Successful treatment of sarcoidosis with leflunomide Rheumatology, May 1, 2003; 42(5): 700 - 702. [Full Text] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				G J GIBSON Sarcoidosis: old and new treatments Thorax, May 1, 2001; 56(5): 336 - 339. [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				G. W. Hunninghake Goal of the Treatment for Sarcoidosis . Minimize Harm for the Patient Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1369 - 1370. [Full Text]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]